

Ozempic® (semaglutide) - New strength

- On March 28, 2022, Novo Nordisk announced the FDA approval of a 2 mg dose of Ozempic (semaglutide).
- Ozempic 2 mg is delivered via a single-patient-use pen. Ozempic was previously available as a single-patient-use pen that delivers 0.25 mg, 0.5 mg, or 1 mg per injection.
- Ozempic is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with T2DM and established cardiovascular disease.
- The efficacy of Ozempic 2 mg was established in a 40-week, double-blind study in 961 patients with T2DM currently treated with metformin with or without sulfonylurea treatment. Patients were randomized to Ozempic 1 mg or 2 mg once weekly.
 - The change in HbA1c at week 40 was 1.9% and 2.1% for Ozempic 1 mg and Ozempic 2 mg (difference of -0.2, 95% CI: -0.31, -0.04; p < 0.01).
- Ozempic carries a boxed warning for risk of thyroid C-cell tumors.
- Ozempic should be started with a 0.25 mg subcutaneous (SC) injection once weekly for 4 weeks.
 The 0.25 mg dosage is intended for treatment initiation and is not effective for glycemic control.
 After 4 weeks on the 0.25 mg dosage, the dosage should be increased to 0.5 mg once weekly.
 - If additional glycemic control is needed after at least 4 weeks on the 0.5 mg dosage, the dosage may be increased to 1 mg once weekly.
 - If additional glycemic control is needed after at least 4 weeks on the 1 mg dosage, the dosage may be increased to 2 mg once weekly. The maximum recommended dosage is 2 mg once weekly.
- Novo Nordisk plans to launch Ozempic 2 mg single-patient-use pens in the second quarter of 2022.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.